We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Novartis To Begin Phase III Clinical Trial of Autoimmune Disease Drug in COVID-19 Patients with Pneumonia

By HospiMedica International staff writers
Posted on 02 May 2020
Print article
Image: Ilaris 150 Mg Injection (Photo courtesy of Novartis).
Image: Ilaris 150 Mg Injection (Photo courtesy of Novartis).
Novartis (Basel, Switzerland) will initiate a Phase III clinical trial to examine the efficacy of utilizing canakinumab, an interleukin (IL)-1β blocker, to treat a type of severe immune overreaction called cytokine release syndrome (CRS) in people with COVID-19 pneumonia.

The study builds on early evidence from lab tests of COVID-19 patients who showed elevated IL-1β levels, among other cytokines. For the CAN-COVID trial, Novartis aims to rapidly enroll 450 patients at multiple medical centers across France, Germany, Italy, Spain, the UK and US and randomize them to receive either canakinumab or placebo on top of standard of care (SoC).

The primary objective of the study is to demonstrate the benefit of canakinumab in combination with SoC in increasing the chance of survival without the need for invasive mechanical ventilation among patients with COVID-19 pneumonia. Top-line results are anticipated late summer 2020.

Related Links:
Novartis

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Pediatric Phlebotomy Chair
2665M2 Extra Wide Pediatric Phlebotomy Chair
New
Body Composition Analyzer
seca mBCA Pro

Print article

Channels

Surgical Techniques

view channel
Image: The stretchy hydrogel and a vial of liquid polymer (Photo courtesy of WPI)

New Class of Bioadhesives to Connect Human Tissues to Long-Term Medical Implants

Medical devices and human tissues differ significantly in their composition. While medical devices are primarily constructed from hard materials like metal and plastic, human tissue is soft and moist.... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more